Expired activity
Please go to the PowerPak
homepage and select a course.
Evolving Therapies for Advanced or Metastatic Breast Cancer: A Focus on CDK 4/6 Inhibition
Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from Pfizer Inc.
OVERVIEW
The management of patients with advanced or metastatic hormone-receptor positive breast cancer (HR-BC) continues to challenge clinicians particularly as a significant number of patients develop resistance to hormonal therapies. The use of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors, a novel class of targeted small molecules, offers an opportunity to revolutionize treatment paradigms by mitigating the development of resistance and by offering alternative options for patients who are resistant. In 2015, the US Food and Drug Administration (FDA) approved the first-in-class CDK 4/6 inhibitor as a novel treatment for patients with HR-BC. A second agent received FDA approval in March 2017, and the role of CDK 4/6 inhibitors was recently incorporated into practice guidelines. Through case-based presentations and expert discussion, this archived webcast will present the most up-to-date information on the use of CDK 4/6 inhibitors in patients with HR-BC, including mechanism of action, clinical trial data, adverse event management, and pharmacist-driven strategies to improve outcomes.
GOAL
The goal of this activity is to provide pharmacists with the most up-to-date information on the use of CDK 4/6 inhibitors in HR-BC.
TARGET AUDIENCE
This activity has been designed to meet the needs of oncology, health system, managed care, specialty pharmacists and other pharmacists who manage patients receiving systemic therapy for HR-positive breast cancer. No prerequisites required.
LEARNING OBJECTIVES
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
- DESCRIBE the MOA of CDK 4/6 inhibition and rationale for use in the treatment of HR-BC.
- EVALUATE clinical trial data for CDK 4/6 inhibitors in the treatment of HR-BC.
- APPLY real-world CDK 4/6 data to patient-specific scenarios related to drug dosing, AE monitoring and patient selection.
CONTINUING EDUCATION INFORMATION
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-17-213-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.
This statement contains information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®. It is recommended that you check your e-profile in CPE Monitor® a few weeks after completion of any CE activity to ensure that your credits are posted. If you don’t see your CE credits correctly displayed from this activity, contact the University of Tennessee College of Pharmacy at jwheele4@uthsc.edu.
Please allow up to 30 days for your credit to appear on CPE Monitor.
Type of Activity: Knowledge
Published: May 10, 2018
Expires: May 10, 2019
Media: Internet
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes
HOW TO EARN CREDIT
Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.
FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:
PARTICIPATING FACULTY
Susan Goodin, PharmD
Executive Director, Statewide Affairs
Rutgers Cancer Institute of New Jersey
Professor of Medicine
Robert Wood Johnson Medical School
New Brunswick, New Jersey
Dr Goodin reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Laura B. Michaud, PharmD, BCOP, FASHP, CMQ
Clinical Pharmacy Manager
University of Texas MD Anderson Cancer Center
Houston, Texas
Dr Michaud reports serving on the advisory board for Pfizer Inc.
OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
GRIEVANCE POLICY
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
ACTIVITY
The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an archived live broadcast, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5
ACTIVITY
The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.
AGENDA
- Preassessment
- Introduction
Susan Goodin, PharmD
- New Therapy for Advanced/Metastatic HR-BC: CDK 4/6 Inhibition
Susan Goodin, PharmD
- Evaluation of Data:
Comparisons of Clinical Trial and Real-World Data
Laura B. Michaud, PharmD, BCOP, FASHP, CMQ
- Case Presentations:
Application to Pharmacy Practice
Susan Goodin, PharmD, and Laura B. Michaud, PharmD, BCOP, FASHP, CMQ
- Conclusions and Q & A
Susan Goodin, PharmD, and Laura B. Michaud, PharmD, BCOP, FASHP, CMQ
- Postassessment and Evaluation
What you are about to see is a previously recorded live meeting. Please note that only "home study" credit will be awarded for participating in this archived presentation. No "live" credits are available.
